Genetown
Filter News
Found 65,494 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
Octreotide, a somatostatin analog, significantly inhibits growth hormone, one of the key drivers of acromegaly.
-
Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
9/18/2020
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020,
-
BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With BPM 31510-IV At The European Society For Medical Oncology (ESMO) 2020 Congress
9/18/2020
BERG, a clinical-stage biotech that employs artificial intelligence (AI) to investigate diseases and develop innovative treatments, today announced two major medical/clinical research developments on pancreatic ductal adenocarcinoma (PDAC) to be presented virtually at the European Society for Medical Oncology (ESMO) 2020 Congress taking place from September 19-21, 2020.
-
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio
9/18/2020
Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda
-
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/18/2020
Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.
-
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
9/18/2020
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S. Wessels to the newly created position of Chief Commercial Officer
-
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
9/18/2020
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors.
-
Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress
9/18/2020
Successfully completed IPO in August 2020 raising $76.6 million in gross proceeds On track to initiate planned new clinical trials in melanoma and head and neck cancer
-
Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of DirectorsIndustry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board
9/18/2020
Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.
-
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
9/18/2020
OncXerna’s RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients
-
Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020
9/18/2020
Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of SNS‑301, a first-in-class bio-engineered, inactivated bacteriophage, in patients with Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
-
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress
9/18/2020
Key Results from Phase 3 ALTA 1L Sub-Analyses Further Support ALUNBRIG’s Strong Intracranial Efficacy and Enhanced Quality of Life in First-Line ALK+ NSCLC
-
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
9/18/2020
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
-
Homology Medicines to Participate in Upcoming Conferences
9/18/2020
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences:
-
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
9/18/2020
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients
-
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
9/18/2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.
-
He also said they would be able to deliver 100 million doses to the U.S. government in the “first few months of 2021.”